Last reviewed · How we verify
Corticotherapy post-transplantation
At a glance
| Generic name | Corticotherapy post-transplantation |
|---|---|
| Sponsor | Nantes University Hospital |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Absence of Steroid in Renal Transplantation and Digital Fibrosis Observation (PHASE4)
- Denosumab for Prevention of Bone Complications After Bone Marrow Transplantation in Children (PHASE1)
- Pharmacodynamics, Efficacy and Safety of Basiliximab 40 or 80 mg in Combination With Ciclosporine Microemulsion or Everolimus, in Adult Low Risk de Novo Renal Transplant Recipients (IDEALE Study) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Corticotherapy post-transplantation CI brief — competitive landscape report
- Corticotherapy post-transplantation updates RSS · CI watch RSS
- Nantes University Hospital portfolio CI